Hildegard Sourgens

from Wikipedia, the free encyclopedia

Hildegard Sourgens (born on February 19, 1948 as Hildegard Ganswindt in Oberhausen ) is a German doctor , specialist in pharmacology and toxicology / specialist in clinical pharmacology .

Life

Hildegard Sourgens studied human medicine from 1966 in Münster and later in Montpellier . From 1968 she was accepted into the German National Academic Foundation . She received her medical license in 1975 and her doctorate in 1977. In 1987 she was appointed Professor of Pharmacology and Toxicology at the University of Münster . From 1989 to 1995 she was director of the Research Institute for Clinical Pharmacology at SmithKlineBeecham in Neuss . In 1989 Sourgens was recognized as a specialist in pharmacology and toxicology and in 1990 for clinical pharmacology.

Her work focuses on the early phase of drug development, as well as endocrinology , development pharmacology, and toxicological evaluation of chemicals . Since 1996 she has been working as an independent appraiser and consultant for the pharmaceutical industry. She is the author of numerous scientific publications and gives many specialist lectures. From 2014 to 2016 she was President of the Working Group for Applied Human Pharmacology ( AGAH ) and from 2017 to 2019 President of the European Federation for Exploratory Medicines Development ( EUFEMED ).

Hildegard Sourgens is privately involved in early music . She and her husband Peter Neubäcker are co-partners and founders of Celemony Software GmbH , which developed the award-winning Melodyne program. She works as a consultant at Celemony.

Hildegard Sourgens lives in Munich.

Publications (selection)

  • T. Hardman, H. Caplain, S. Rotterey, D. Douglas, S. Stringer and H. Sourgens: European Federation for Exploratory Medicines Development Lyon Conference 2019 in The Changing Landscape of Early Medicines Development — Be Prepared. Front. Pharmacol. 10: 1377. doi: 10.3389 / fphar.2019.01377 .
  • K. Breithaupt-Groegler, T. Hardman, J. De Hoon, Y. Donazzolo, S. Rotterey, H. Sourgens and S. Stringer: The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum. Front Pharmacol. 2019 Apr 24; 10:398. doi: 10.3389 / fphar.2019.00398 .
  • H. Sourgens, MA Bertola, JSC Verschoor, M. Kuipers and B. Rayer: Amoxicillin / clavulanic acid (875/125): bioequivalence of a novel Solutab (R) tablet and rationale for a twice-daily dosing regimen. International Journal of Clinical Pharmacology and Therapeutics, 2004, Vol. 42, No. 2, 165-173.
  • H. Sourgens, J. Schmidt, H. Derendorf: Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. Int. J. Clin. Pharmacol. 2003, Ther. 41, 22-9.
  • H. Sourgens: Drug Interactions: Endangering Substitution . In: Christian Jellinek / Bernd Westermann / Gabriele U. Bellmann (eds.) Beigebrauch - Open Limits of Substitution. Beltz, Weinheim 2000, ISBN 3892719306 .
  • H. Sourgens: Considerations on Ars medica using the example of new developments in clinical pharmacology . In: Peter Kröner et al .: ars medica - the lost unity of medicine. Fischer, Stuttgart 1994, ISBN 9783437116018 , pp. 211-224.

Lectures (selection)

  • Solved problems and unsolved challenges in applied human pharmacology . AGAH Annual Meeting, Hamburg, February 2010, pp. 21-23.
  • Clinical development programs for biosimilars . Plenary lecture, AGAH Annual Meeting Weimar, April 18 and 19, 2008.
  • Pregnancy in the context of clinical studies, a medical indication for abortion? AGAH autumn conference, Göttingen 1994.

Web links

Individual evidence

  1. Hildegard Sourgens on www.docplayer.de
  2. career by Hildegard Sourgens , accessed on November 11, 2019
  3. Celemony - The Team. celemony.com, accessed November 19, 2019 .